Compare Stocks

→ The only accurate crypto trading system I know … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLBS Caladrius Biosciences		$6.37	$0.38 ▼ $1.24	$26.05M	0.91	522,308 shs	466,373 shs
CTYX Curative Biotechnology	$0.03	$0.03	$0.00 ▼ $0.22	$10.44M	-33.99	3.01 million shs	21,466 shs
EMMA Emmaus Life Sciences	$0.11	$0.11	$0.05 ▼ $0.35	$7.04M	1.61	2,694 shs	N/A
GRNV GreenVision Acquisition		$10.89	$7.70 ▼ $25.30	$37K	0.07	105,738 shs	1.54 million shs

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLBS Caladrius Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
CTYX Curative Biotechnology	-4.07%	+11.92%	-5.75%	+3.31%	+58.00%
EMMA Emmaus Life Sciences	0.00%	+8.33%	+32.73%	+42.19%	-65.53%
GRNV GreenVision Acquisition	0.00%	0.00%	0.00%	-61.93%	-99.35%

The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLBS Caladrius Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CTYX Curative Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EMMA Emmaus Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GRNV GreenVision Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLBS Caladrius Biosciences	N/A	N/A	N/A	N/A
CTYX Curative Biotechnology	N/A	N/A	N/A	N/A
EMMA Emmaus Life Sciences	N/A	N/A	N/A	N/A
GRNV GreenVision Acquisition	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLBS Caladrius Biosciences	N/A	N/A	N/A	N/A	$1.54 per share	N/A
CTYX Curative Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A
EMMA Emmaus Life Sciences	$18.39M	0.38	N/A	N/A	($0.69) per share	-0.16
GRNV GreenVision Acquisition	N/A	N/A	N/A	N/A	$0.70 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLBS Caladrius Biosciences	-$27.47M	-$0.41	N/A	N/A	N/A	N/A	-27.24%	-26.08%	N/A
CTYX Curative Biotechnology	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
EMMA Emmaus Life Sciences	-$10.62M	-$0.10	N/A	∞	N/A	-16.66%	N/A	-9.73%	N/A
GRNV GreenVision Acquisition	-$510K	N/A	0.00	N/A	N/A	N/A	-54.82%	-2.65%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLBS Caladrius Biosciences	N/A	N/A	N/A	N/A	N/A
CTYX Curative Biotechnology	N/A	N/A	N/A	N/A	N/A
EMMA Emmaus Life Sciences	N/A	N/A	N/A	N/A	N/A
GRNV GreenVision Acquisition	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLBS Caladrius Biosciences	N/A	22.33	22.33
CTYX Curative Biotechnology	N/A	N/A	N/A
EMMA Emmaus Life Sciences	N/A	0.15	0.12
GRNV GreenVision Acquisition	N/A	0.29	0.29

Ownership

Institutional Ownership

Company	Institutional Ownership
CLBS Caladrius Biosciences	15.57%
CTYX Curative Biotechnology	N/A
EMMA Emmaus Life Sciences	7.42%
GRNV GreenVision Acquisition	N/A

Insider Ownership

Company	Insider Ownership
CLBS Caladrius Biosciences	2.20%
CTYX Curative Biotechnology	N/A
EMMA Emmaus Life Sciences	35.00%
GRNV GreenVision Acquisition	42.90%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CLBS Caladrius Biosciences	27	60.58 million	59.25 million	Optionable
CTYX Curative Biotechnology	N/A	388.50 million	N/A	Not Optionable
EMMA Emmaus Life Sciences	54	61.85 million	40.20 million	Not Optionable
GRNV GreenVision Acquisition	N/A	3.35 million	N/A	Not Optionable

CLBS, EMMA, CTYX, and GRNV Headlines

Source	Headline
	Helbiz IPO (HLBZ) Stock benzinga.com - August 20 at 6:09 PM
	SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of GreenVision Acquisition Corp. (Nasdaq fintechzoom.com - August 17 at 1:37 AM
	Scooter-Share Helbiz’s Friday 13th Debut Shows SPAC Refunds finance.yahoo.com - August 13 at 5:28 PM
	Why GreenVision's Stock Is Skyrocketing Today msn.com - August 13 at 5:28 PM
	Helbiz, Inc. and Greenvision Acquisition Corp. Announce Closing of Business Combination; Helbiz to Trade on Nasdaq Under Symbol "HLBZ" finance.yahoo.com - August 13 at 8:04 AM
	Helbiz Partners with Lightning eMotors to Deploy Electric Vehicles for Fleet Management finance.yahoo.com - July 30 at 8:47 AM
	Micro-Mobility Leader, Helbiz, Launches E-Scooters in Reggio Emilia, Italy finance.yahoo.com - July 26 at 12:47 PM

Media Sentiment Over Time

Company Descriptions

Caladrius Biosciences

NASDAQ:CLBS

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Curative Biotechnology

OTCMKTS:CTYX

Curative Biotechnology, Inc. engages in the provision of software solutions for the healthcare market. Its products include MedFlash, electronic Personal Health Manager, Medical Alert, personal emergency response services, product and medical transcription, disease management, revenue cycle management, and medical consulting-billing. The company was founded by Jon Pevzner on July 29, 1995 and is headquartered in Boca Raton, FL.

Emmaus Life Sciences

OTCMKTS:EMMA

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.

GreenVision Acquisition

NASDAQ:GRNV

As of April 1, 2021, operates as a subsidiary of Helbiz, Inc..

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial